Anti-Nephrin Autoantibodies, Precision in Nephrotic Syndrome

In this episode, the spotlight shifts to anti-nephrin autoantibodies as a key example of deeper mechanistic understanding transforming care in minimal change disease and idiopathic nephrotic syndrome.

Huber begins by noting that the term “minimal change” belies the severity of these conditions. For example, patients can be profoundly nephrotic despite seemingly minor histologic changes, and many children historically carried the vague label “idiopathic nephrotic syndrome” because the underlying cause was unknown.1

Over the last 2 years, evidence has accumulated that most of these cases are driven by autoantibodies, specifically anti-nephrin antibodies. Huber cites data suggesting that roughly 70% of adult minimal change disease and up to 90% of idiopathic nephrotic syndrome in children are associated with these antibodies. This reframes what was once idiopathic as a largely autoimmune, antibody-mediated disease.

He outlines 3 major implications:

1. Diagnostics: Anti-nephrin antibodies can serve as a diagnostic marker, helping to identify and categorize patients more precisely than broad histologic labels.
2. Prognosis and treatment response: Antibody levels may help predict outcomes and response to therapy, allowing clinicians to anticipate which patients will benefit from specific interventions.
3. Therapeutic targeting: Recognizing that disease is antibody-driven supports a shift from steroid-heavy regimens toward B cell–modifying or depleting therapies, aligning treatment with the underlying immunopathology.

Huber stresses that a key barrier today is the confinement of testing mainly to academic laboratories. To begin to impact daily nephrology practice, the field must develop standardized, commercially available, certified assays. He shares his center’s experience, where these antibodies are used to make diagnoses, guide treatment choices, monitor response, and even prepare for transplantation, for example, depleting antibodies in patients at high risk of recurrent FSGS post-transplant.2

The episode underscores the potential for anti-nephrin testing to reduce reliance on steroids, improve timing of therapeutic changes, and move glomerular disease care further into the realm of precision medicine, provided access to robust assays becomes widespread.

Featured Experts

Barbara Gillespie, MD, Chief Medical and Strategy Officer of the International Society of Glomerular Disease and Adjunct Professor at the University of North Carolina

Tobias Huber, MD, President of the International Society of Glomerular Disease, Chair of the Center of Internal Medicine; Director of the III. Department of Medicine (Nephrology, Rheumatology, Endocrinology and Transplantation); and Director of the Hamburg Center for Kidney Health at the University Medical Center Hamburg-Eppendorf

Editors’ Note: Gillespie reports no relevant disclosures. Huber reports relevant disclosures with Boehringer Ingelheim, Novartis, Alexion, Pfizer, Retrophin-Travere, and Fresenius Medical Care.

References

1. Hillenbrand A. Adolescents, Young Adults With Glomerular Disease May Require Distinct Care. HCPLive. Published January 7, 2026. Accessed March 6, 2026. https://www.hcplive.com/view/young-adults-glomerular-disease-distinct-care

2. Kunzmann K. Glomerulonephritis Patients Face High Risk of Recurrence After Kidney Transplant. HCPLive. Published April 27, 2024. Accessed March 6, 2026. https://www.hcplive.com/view/glomerulonephritis-patients-high-risk-recurrence-kidney-transplant